Results 101 to 110 of about 44,395 (311)

Patterns of activation of vanilloid and purinergic receptors of the bladder urothelium in elderly with hyperfunction of urothelium, atherosclerosis and their combination

open access: yesКлиническая практика, 2018
This article describes the patterns of activation of vanilloid and purinergic receptors in the bladder tissue in males of different ages. Based on the obtained data, the conclusions are made about the prospects of using activation of these receptors as ...
K. I. Prashchaev   +4 more
doaj   +1 more source

Benign prostatic hyperplasia : Part 2-management [PDF]

open access: yes, 2008
Peer reviewedPublisher ...
N'Dow, James, Wilt, Timothy J
core   +2 more sources

Which Patients With Dysfunctional Voiding Respond Well to Sacral Neuromodulation? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims Dysfunctional voiding (DV) is characterised by fluctuating or intermittent urinary flow during voiding in neurologically normal individuals. Given the different definitions used and heterogeneous pathophysiologies, outcomes following sacral neuromodulation/sacral nerve stimulation (SNM/SNS) are variably reported.
Jalesh N. Panicker   +8 more
wiley   +1 more source

Clinical use of the beta-3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome [PDF]

open access: yes, 2015
Mirabegron is a β 3 adrenoceptor agonist licensed for the treatment of overactive bladder symptoms, such as urinary urgency or urgency incontinence. β 3 adrenoceptor activation causes detrusor muscle relaxation, but mirabegron may also act by binding ...
Drake, Marcus, Vij, Monika
core   +2 more sources

What Is Required for AI to Improve the Assessment and Treatment of Patients With Lower Urinary Tract Dysfunction? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Artificial intelligence (AI) is poised to improve the diagnosis and management of lower urinary tract dysfunction (LUTD). Its effective deployment requires prioritization, regulatory oversight, rigorous validation, and clinician and patient engagement.
Glenn T. Werneburg   +15 more
wiley   +1 more source

Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients [PDF]

open access: yes, 2018
Background. Chronic kidney disease (CKD) is a highly prevalent condition. Urologic disorders are known causes of CKD, but often remain undiagnosed and underestimated also for their insidious onset and slow progression.
Ciccariello, Mauro   +12 more
core  

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk   +7 more
wiley   +1 more source

New technologies in the management of overactive bladder: current research and future prospects

open access: yesTherapeutic Advances in Urology, 2019
Overactive bladder is characterized by frequency, urgency (wet or dry) and nocturia. These troublesome symptoms incur both a physiologic and economic cost, expected to be in excess of US$82 billion in the USA and Europe by the year 2020.
Serge P. Marinkovic
doaj   +1 more source

Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study [PDF]

open access: yes, 2016
We investigated the efficacy and tolerability of solifenacin 5 mg fixed dose in children with newly diagnosed idiopathic overactive bladder (OAB). A total of 34 children (male/female patients = 16/18) aged under 13 years (mean age: 7.2 +/- 2.3; range: 5 ...
Alloussi   +26 more
core   +1 more source

Home - About - Disclaimer - Privacy